<ul><li>Natco Pharma reported a slower-than-expected earnings growth in Q4 FY25 with a 5.3% rise in consolidated net profit to Rs 407 crore, missing analysts' estimate of Rs 587 crore.</li><li>The company saw a 14.3% increase in revenue from operations to Rs 1,221 crore, falling short of the projected Rs 1,387 crore.</li><li>Higher expenses on raw materials impacted the Ebitda margin, which stood at 44.9% versus the estimated 52.5%.</li><li>Natco Pharma anticipates a decline in revenue by 20% and profit by 30% in FY26 due to geopolitical uncertainties, pricing pressure in the US, and increased R&D expenses arising from Trump administration's tariff policies.</li></ul>

Natco Pharma Q4 Results: Profit Misses Estimates, Margin Contracts; FY26 Outlook Gloomy

Discover more